Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Clinical Trials

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Phase 2

Terminated

Conditions: Non-Malignant Hematologic Disorders

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Clofarabine
Drug: Fludarabine
Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Procedure: CliniMACS reagents

First Posted Date: 2018-08-03

Last Posted Date: 2021-03-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT03615144

Locations: 🇺🇸
Memorial SloanKettering Cancer Center, New York, New York, United States

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoid Leukemia (ALL)
Chronic Myeloid Leukemia (CML)
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

Interventions: Radiation: Hyperfractionated total body irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Fludarabine
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Clofarabine
Procedure: HPC(A) stem cell allograft
Drug: Rituximab
Device: Rabbit antithymocyte globulin

First Posted Date: 2018-08-03

Last Posted Date: 2025-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03615105

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed

Conditions: Immune Deficiency
Thalassemia
Hemoglobinopathies
Fanconi Anemia
Sickle Cell Disease
Nonmalignant Diseases
Hematologic Malignancies
Genetic Inborn Errors of Metabolism

Interventions: Drug: Thiotepa

First Posted Date: 2018-08-01

Last Posted Date: 2023-09-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT03609840

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Phase 1

Active, not recruiting

Conditions: Severe Combined Immunodeficiency

Interventions: Drug: Anti-thymocyte globulin (rabbit)
Drug: Busulfan
Other: Donor Lymphocyte Infusion
Drug: Fludarabine
Drug: Thiotepa
Device: CliniMACS

First Posted Date: 2018-07-24

Last Posted Date: 2024-06-12

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT03597594

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Emphysema or COPD

Interventions: Biological: CD3/CD19 negative hematopoietic stem cells
Drug: Rituximab
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Thiotepa
Drug: G-CSF
Drug: Hydroxyurea

First Posted Date: 2018-04-18

Last Posted Date: 2025-01-09

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 8

Registration Number: NCT03500731

Locations: 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome With Excess Blasts

Interventions: Biological: Dilanubicel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
Other: Laboratory Biomarker Analysis
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Procedure: Multigated Acquisition Scan
Procedure: Electrocardiography
Procedure: Computed Tomography

First Posted Date: 2018-01-16

Last Posted Date: 2025-04-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03399773

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma

Phase 2

Completed

Conditions: Malignant Lymphoma

Interventions: Drug: Thiotepa

First Posted Date: 2017-11-17

Last Posted Date: 2024-07-09

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 50

Registration Number: NCT03346096

Locations: 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Fludarabine

First Posted Date: 2017-11-14

Last Posted Date: 2025-03-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 39

Registration Number: NCT03342196

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Procedure: Haploidentical Bone Marrow Transplantation
Drug: Hydroxyurea
Drug: Rabbit-ATG
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Drug: Mesna

First Posted Date: 2017-08-28

Last Posted Date: 2025-04-27

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 95

Registration Number: NCT03263559

Locations: 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States

and more 29 locations

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

Phase 2

Terminated

Conditions: Very High Risk Neuroblastoma

Interventions: Radiation: mIBG
Drug: Thiotepa
Drug: Topotecan
Procedure: Autologous stem cell transplant

First Posted Date: 2017-05-24

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 34

Registration Number: NCT03165292

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇦🇹
St. Anna Kinderspital GmbH, Vienna, Austria
🇮🇹
Fondazione IRCCS Istituto nazionaleTumori, Milano, Italy

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy